Literature DB >> 27181397

Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.

T Raymond Foley1, Stephen W Waldo1, Ehrin J Armstrong2.   

Abstract

OPINION STATEMENT: Peripheral artery disease (PAD) comprises atherosclerosis of the aorta and lower extremities. Many patients with PAD are asymptomatic, while others present with intermittent claudication (IC) or critical limb ischemia (CLI). Defined as rest pain or tissue loss that persists for >2 weeks, CLI represents the most severe clinical manifestation of PAD and is associated with an increased risk of limb loss and death. Patients with PAD, including those with CLI, are underdiagnosed and undertreated. In addition to smoking cessation, medical therapy with an antiplatelet agent and statin is recommended for all patients with PAD. Regular exercise has been shown to improve walking distance and quality of life in patients with symptomatic PAD and should be incorporated into each patient's treatment plan. In patients who have CLI and in those with persistent lifestyle-limiting claudication despite optimal medical therapy and an exercise program, revascularization is indicated for limb salvage and symptom relief, respectively. Consensus guidelines currently support an endovascular first approach to revascularization in the majority of cases. Surgical procedures provide an alternative to endovascular therapy in select cases.

Entities:  

Keywords:  Critical limb ischemia; Peripheral artery disease; Therapy; Vascular disease

Year:  2016        PMID: 27181397     DOI: 10.1007/s11936-016-0464-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  89 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.

Authors:  B L W Bendermacher; E M Willigendael; J A W Teijink; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial.

Authors:  Miguel Ruiz-Canela; Ramón Estruch; Dolores Corella; Jordi Salas-Salvadó; Miguel A Martínez-González
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

Review 4.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

5.  Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.

Authors:  Ehrin J Armstrong; David R Anderson; Khung-Keong Yeo; Gagan D Singh; Heejung Bang; Ezra A Amsterdam; Julie A Freischlag; John R Laird
Journal:  J Vasc Surg       Date:  2015-04-08       Impact factor: 4.268

6.  Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.

Authors:  Pingping Huang; Shangzhu Li; Mingzhe Han; Zhijian Xiao; Renchi Yang; Zhong Chao Han
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 7.  Hyperbaric oxygen therapy for chronic wounds.

Authors:  Peter Kranke; Michael H Bennett; Marrissa Martyn-St James; Alexander Schnabel; Sebastian E Debus
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Mori J Krantz; John M Kittelson; William R Hiatt
Journal:  JAMA       Date:  2009-05-13       Impact factor: 56.272

Review 10.  Cilostazol for peripheral arterial disease.

Authors:  P Robless; D P Mikhailidis; G P Stansby
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  5 in total

1.  ETV-2 activated proliferation of endothelial cells and attenuated acute hindlimb ischemia in mice.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Hoa Trong Nguyen; Thuy Thi-Thanh Dao; Ha Thi-Ngan Le; Lan Thi Phi; Oanh Thi-Kieu Nguyen; Ngoc Kim Phan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-04-19       Impact factor: 2.416

2.  Hypoxia pretreatment improves the therapeutic potential of bone marrow mesenchymal stem cells in hindlimb ischemia via upregulation of NRG-1.

Authors:  Xitao Peng; Bing Liang; Haisheng Wang; Jingyuan Hou; Qidong Yuan
Journal:  Cell Tissue Res       Date:  2022-01-29       Impact factor: 5.249

Review 3.  Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis.

Authors:  Bronte Miller; Mary Kathryn Sewell-Loftin
Journal:  Front Cardiovasc Med       Date:  2022-01-11

4.  Influence of Nursing Intervention Based on Risk Assessment Model on Self-Efficacy and Postoperative Rehabilitation of Surgical Patients.

Authors:  Yanfang Yang; Peng Chen; Cuili Jiao
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

5.  Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.

Authors:  Yongchao Zhao; Jingjing Hu; Xiaolei Sun; Kun Yang; Lebing Yang; Lingqiu Kong; Beijian Zhang; Fuhai Li; Chaofu Li; Bei Shi; Kai Hu; Aijun Sun; Junbo Ge
Journal:  Clin Transl Med       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.